


# Germ-line *BRCA1/2* testing recommended in ovarian cancer

June 19 2012

---



Due to the potential survival and treatment response implications of *BRCA* mutation status, it is recommended that germ-line *BRCA1/2* testing be offered to all women diagnosed with nonmucinous ovarian carcinoma, regardless of family history, according to research published online June 18 in the *Journal of Clinical Oncology*.

(HealthDay) -- Due to the potential survival and treatment response implications of *BRCA* mutation status, it is recommended that germ-line *BRCA1/2* testing be offered to all women diagnosed with nonmucinous ovarian carcinoma, regardless of family history, according to research published online June 18 in the *Journal of Clinical Oncology*.

To investigate the impact of germ-line *BRCA1* and *BRCA2* mutations in ovarian cancer, Kathryn Alsop, of the Peter MacCallum Cancer Centre in East Melbourne, Australia, and colleagues screened 1,001 women with nonmucinous ovarian carcinomas enrolled in a case-control study for germ-line point mutations and large deletions in *BRCA1* and *BRCA2*

genes.

The researchers found that 14.1 percent of patients exhibited *BRCA1/2* germ-line mutations. Of these, 16.6 percent had serous cancer and 44 percent reported no family history of either breast or ovarian cancer. Compared with women without germ-line mutations, patients with germ-line mutations had improved rates of progression-free and overall survival and tended to respond to platin and nonplatin-based regimens in the relapse setting. Somatic *BRCA1/2* mutations were more likely to be found in mutation-negative patients who responded to multiple cycles of platin-based treatment.

"Our findings suggest changes in the guidelines for genetic testing of all invasive ovarian cancer patients, indicate that the measurement of *BRCA* status should be explicitly integrated into future clinical trial designs as a major stratification factor, and declare *BRCA* status is now ready to be included in the [clinical management](#) of women with [ovarian cancer](#)," the authors write.

**More information:** [Abstract](#)  
[Full Text \(subscription or payment may be required\)](#)

Copyright © 2012 [HealthDay](#). All rights reserved.

Citation: Germ-line *BRCA1/2* testing recommended in ovarian cancer (2012, June 19) retrieved 27 April 2024 from  
<https://medicalxpress.com/news/2012-06-germ-line-ibrca12i-ovarian-cancer.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------